EUpolicy

R&D

How Europe can harness the full potential of biosimilars

Biosimilars - clinically equivalent alternatives to original biologic drugs - play a vital role in addressing unmet health needs.

R&D

No longer the little fish: How Europe is holding its own thr...

It goes without saying that we are living in uncertain times, yet, this holds particularly true for the pharmaceutical industry.

Market Access

neurotech representation of head in code

Neurotech patents in Europe: Methods, medical devices, and t...

The field of neurotechnology is rapidly evolving, bringing together advances in neuroscience, engineering, materials science, and computing.

Market Access

Early strategic evidence planning is a key success factor in...

As the European Union (EU) ushers in a new era of health technology regulation, pharmaceutical companies face both unprecedented challenges and opportunities.

How Europe can harness the full potential of biosimilars

No longer the little fish: How Europe is holding its own thr...

Neurotech patents in Europe: Methods, medical devices, and t...

Early strategic evidence planning is a key success factor in...

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

EUpolicy

Editor's Picks